Access Tempus Stock and Financial Details

Q: Can you buy Tempus stock?

You can no longer buy Tempusstock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

Enterprise Value

Access valuation and stock price for companies like Tempus before its IPO.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Tempus stock FAQs

Can you buy Tempus stock?

You can no longer buy Tempus stock on a secondary marketplace as this company is no longer private. If you are interested in buying stock of other private companies, learn more about how to invest in the private market or register today to get started.

How to buy Tempus stock?

To invest in a private company like Tempus through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Tempus stock?

You can no longer sell stock of Tempus on Forge as this company is no longer private. However, if you own stock of a private company, Forge may help you sell it in a way that works for you and the company. Learn more or register with us today to get started.

How to sell Tempus stock?

If you hold private company shares of Tempus - whether as an employee or an early investor - Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Tempus stock on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

Is Tempus a public company?

No, Tempus is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Tempus’ stock ticker symbol?

The ticker symbol of Tempus is TEM.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Tempus investors also invested in these private companies

Team

Management Team

Kevin White, Ph.D.

Chief Science Officer

Vanessa Rollings

Chief Financial Officer

Eric Lefkofsky

Founder & Chief Executive Officer

Ryan Fukushima

Chief Operating Officer

Marc Yoskowitz

Chief Strategy Officer

Mike Yasiejko

Chief Commercial Officer

Gary Palmer, MD

Chief Medical Officer

Shane Colley

Chief Technology Officer

Chief Strategy Officer

Chief People Officer

Board Members

David Agus, MD

A. Keith Stewart, MB.CHB., MBA

Steve Case

Revolution

Arul M. Chinnaiyan, MD, Ph.D.

Peter Barris

New Enterprise Associates

Funmi Olopade, MD

Eric Topol, MD

John Doerr

Kleiner Perkins

Reuters 06/05/2024

SoftBank-backed Tempus AI seeks up to $6.1 bln valuation in US IPO

Tempus is reportedly planning a public offering.

Bloomberg 05/20/2024

Tempus AI Files for US IPO Touting ‘Intelligent Diagnostics’

Tempus is joining a host of other companies for an initial public offering.

Yahoo Finance 12/05/2023

SkylineDx Announces Commercial Collaboration with Tempus to Advance Patient Care with its Merlin Test

Tempus, a biotechnology research company providing physicians with AI-enabled medicine solutions, is collaborating with SkylineDx to make their Merlin Test more accessible to melanoma cancer patients in the U.S. The test assesses the metastasis risk on a patient’s sentinel lymph nodes based on genes from the main tumor, tumor thickness, and the patient’s age. The collaboration between Tempus and SkylineDx will give healthcare providers better insights into early-stage treatment options depending on each patient’s need.

Genomeweb 04/12/2022

Tempus, Pyramid Biosciences to ID Patients With NTRK Fusion-Driven Cancers for Clinical Trial

Pyramid will use Tempus' TIME Trial Network to identify and enroll patients eligible for a Phase I/II trial of its TRK inhibitor, PBI-200.

Tempus Stock

Register To Buy and Sell Private Company Shares